Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other financing activities (2018 - 2024)

Crinetics Pharmaceuticals has reported Other financing activities over the past 3 years, most recently at -$967000.0 for Q4 2024.

  • Quarterly results put Other financing activities at -$967000.0 for Q4 2024, down 125.41% from a year ago — trailing twelve months through Dec 2025 was $3.4 million (up 14.65% YoY), and the annual figure for FY2024 was $15.0 million, up 57523.08%.
  • Other financing activities for Q4 2024 was -$967000.0 at Crinetics Pharmaceuticals, down from $4.3 million in the prior quarter.
  • Over the last five years, Other financing activities for CRNX hit a ceiling of $4.3 million in Q1 2024 and a floor of -$967000.0 in Q4 2024.